GLP-1 RAs have been approved in the treatment of T2DM for improving HbA1c and for reducing the risk of major adverse cardiac events (MACE) in diabetes patients with cardiovascular risk [23,24]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.